Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.08 USD
+2.83 (2.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
by Zacks Equity Research
Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.
5 Biotech Stocks to Consider for Your Portfolio in 2024
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
by Zacks Equity Research
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
by Zacks Equity Research
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
by Zacks Equity Research
Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.
Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
by Zacks Equity Research
Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
by Zacks Equity Research
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.
STERIS (STE) Set to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2024 results are likely to reflect solid performance across both the Healthcare and AST segments.
IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.
Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
by Zacks Equity Research
Jasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
by Zacks Equity Research
Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
by Zacks Equity Research
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 29.5% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.
TransCode (RNAZ) Down 50% on Issue of New Common Stock
by Zacks Equity Research
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
by Zacks Equity Research
ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
by Zacks Equity Research
Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.